
Jinal N Bhiman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/648038/publications.pdf Version: 2024-02-01



Ιίναι Ν Βηιμαν

#	Article	IF	CITATIONS
1	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, The, 2022, 399, 437-446.	13.7	818
2	T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature, 2022, 603, 488-492.	27.8	430
3	Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. Clinical Infectious Diseases, 2022, 75, e144-e156.	5.8	32
4	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	27.8	1,210
5	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. Journal of Virological Methods, 2022, 302, 114471.	2.1	8
6	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 2022, 602, 654-656.	27.8	928
7	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports, 2022, 12, 2552.	3.3	23
8	SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. Lancet Infectious Diseases, The, 2022, 22, 821-834.	9.1	74
9	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. Molecular Biology and Evolution, 2022, 39, .	8.9	84
10	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virus–Infected and Uninfected Persons: A Cross-Sectional Household Survey. Clinical Infectious Diseases, 2022, 75, e57-e68.	5.8	11
11	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nature Communications, 2022, 13, 1976.	12.8	27
12	Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature, 2022, 607, 356-359.	27.8	66
13	Leveraging South African <scp>HIV</scp> research to define <scp>SARSâ€CoV</scp> â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	6.0	6
14	SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts. Science Translational Medicine, 2022, 14, .	12.4	36
15	An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115.	30.7	47
16	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nature Medicine, 2022, 28, 1785-1790.	30.7	456
17	Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine, 2021, 27, 440-446.	30.7	326
18	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	27.8	1,381

Jinal N Bhiman

#	Article	IF	CITATIONS
19	SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine, 2021, 27, 622-625.	30.7	984
20	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	27.0	1,077
21	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine, 2021, 384, 2161-2163.	27.0	111
22	SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nature Microbiology, 2021, 6, 821-823.	13.3	221
23	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	11.0	73
24	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature Communications, 2021, 12, 4817.	12.8	35
25	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. The Lancet Global Health, 2021, 9, e1216-e1225.	6.3	131
26	SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021. Emerging Infectious Diseases, 2021, 27, 3020-3029.	4.3	78
27	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	12.6	144
28	A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Science Immunology, 2021, 6, eabf1152.	11.9	63
29	COVID-19 testing in Africa: lessons learnt. Lancet Microbe, The, 2020, 1, e103-e104.	7.3	65
30	Genome Sequencing of a Severe Acute Respiratory Syndrome Coronavirus 2 Isolate Obtained from a South African Patient with Coronavirus Disease 2019. Microbiology Resource Announcements, 2020, 9,	0.6	8
31	A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe, The, 2020, 1, e229-e230.	7.3	46
32	Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 2020, 26, 430-440.	30.7	172
33	Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Scientific Reports, 2020, 10, 6201.	3.3	22
34	Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Cell Reports, 2019, 29, 1756-1766.e8.	6.4	47
35	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathogens, 2019, 15, e1008005.	4.7	6
36	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	6.4	23

Jinal N Bhiman

#	Article	IF	CITATIONS
37	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host and Microbe, 2018, 24, 593-599.e3.	11.0	24
38	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nature Communications, 2018, 9, 4136.	12.8	11
39	Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Current Opinion in Immunology, 2018, 53, 143-151.	5.5	105
40	Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. Immunity, 2017, 46, 762-764.	14.3	3
41	Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Current HIV/AIDS Reports, 2017, 14, 54-62.	3.1	18
42	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
43	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
44	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
45	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine, 2015, 21, 1332-1336.	30.7	215
46	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. AIDS Research and Human Retroviruses, 2014, 30, A20-A21.	1.1	1
47	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
48	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	4.7	190
49	Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 2012, 18, 1688-1692.	30.7	273
50	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	27.8	61
51	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 0, , .	27.8	104